Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001493152-22-032117
Q2 2023 · 10-Q
Revenue$8.59M$8.59M +0.3% vs Q2 2022+11.9% vs Q1 2023
Net Income$1.52M$1.52M −15.7% vs Q2 2022+395.3% vs Q1 2023
EPS Diluted$0.00$0.00 — vs Q2 2022no prior Q1 2023 on file
Gross Profit$3,824,434+1.5%
Operating Income$1,081,117−24.0%
Operating Cash Flowderived$1,495,414+872.4%
Free Cash Flowderived-$3,609,685—
Margins · derived
Gross margin44.5%+0.5 pt vs Q2 2022
Operating margin12.6%−4.0 pt vs Q2 2022
Net margin17.6%−3.3 pt vs Q2 2022
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $8.59M | $8.56M | $7.40M | $4.63M |
| Net Income | $1.52M | $1.80M | $2.48M | -$1.60M |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR